Kenilworth

May 21, 2019

Merck Animal Health Introduces BRAVECTO® Cares to Show Support for the Health of Service Dogs

Jun 26, 2018

Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA®

Jun 07, 2018

4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours

Apr 10, 2018

BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®

Feb 19, 2018

BerGenBio Completes Recruitment Into First Stage of Phase II Breast Cancer Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®

Jan 29, 2018

BerGenBio: Encouraging I-O Clinical Data With Selective AXL Inhibitor Bemcentinib (BGB324) Supports its Potential as Cornerstone of Cancer Therapy

Dec 08, 2017

Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS

Oct 02, 2017

SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA